TY - JOUR
T1 - Exploring the Molecular Complexity of Medulloblastoma
T2 - Implications for Diagnosis and Treatment
AU - Rechberger, Julian S.
AU - Toll, Stephanie A.
AU - Vanbilloen, Wouter J.F.
AU - Daniels, David J.
AU - Khatua, Soumen
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - Medulloblastoma is the most common malignant brain tumor in children. Over the last few decades, significant progress has been made in revealing the key molecular underpinnings of this disease, leading to the identification of distinct molecular subgroups with different clinical outcomes. In this review, we provide an update on the molecular landscape of medulloblastoma and treatment strategies. We discuss the four main molecular subgroups (WNT-activated, SHH-activated, and non-WNT/non-SHH groups 3 and 4), highlighting the key genetic alterations and signaling pathways associated with each entity. Furthermore, we explore the emerging role of epigenetic regulation in medulloblastoma and the mechanism of resistance to therapy. We also delve into the latest developments in targeted therapies and immunotherapies. Continuing collaborative efforts are needed to further unravel the complex molecular mechanisms and profile optimal treatment for this devastating disease.
AB - Medulloblastoma is the most common malignant brain tumor in children. Over the last few decades, significant progress has been made in revealing the key molecular underpinnings of this disease, leading to the identification of distinct molecular subgroups with different clinical outcomes. In this review, we provide an update on the molecular landscape of medulloblastoma and treatment strategies. We discuss the four main molecular subgroups (WNT-activated, SHH-activated, and non-WNT/non-SHH groups 3 and 4), highlighting the key genetic alterations and signaling pathways associated with each entity. Furthermore, we explore the emerging role of epigenetic regulation in medulloblastoma and the mechanism of resistance to therapy. We also delve into the latest developments in targeted therapies and immunotherapies. Continuing collaborative efforts are needed to further unravel the complex molecular mechanisms and profile optimal treatment for this devastating disease.
KW - adoptive cell therapy
KW - chemotherapy
KW - diagnosis
KW - epigenetic machinery
KW - immunotherapy
KW - medulloblastoma
KW - molecular subtypes
KW - radiation therapy
KW - targeted therapy
KW - therapeutic resistance
UR - http://www.scopus.com/inward/record.url?scp=85174553449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174553449&partnerID=8YFLogxK
U2 - 10.3390/diagnostics13142398
DO - 10.3390/diagnostics13142398
M3 - Review article
AN - SCOPUS:85174553449
SN - 2075-4418
VL - 13
JO - Diagnostics
JF - Diagnostics
IS - 14
M1 - 2398
ER -